Press Release: Wexford Capital : AZTherapies Announces Closing of $33.6 Million Series C-1 Financing Building Upon Recent $37.5 Million Series C Financing

Proceeds will help AZTherapies expand regulatory and pre-commercial activities related to Phase 3 candidate for early Alzheimer's disease and advance other neuroinflammation-targeted programsProceeds will help AZTherapies expand regulatory and pre-commercial activities related to Phase 3 candidate for early Alzheimer's disease and advance other neuroinflammation-targeted programs